Eric brings over 30 years of experience in the development of biopharmaceuticals, cell therapies, and regenerative medicine products
VANCOUVER, British Columbia – July 21, 2020 – Aspect Biosystems, a biotechnology platform company pioneering the microfluidic 3D bioprinting of human tissues, is pleased to announce the appointment of Eric Roos as its new Chief Business Development Officer.
Eric comes to Aspect with over 30 years in biotechnology with experience in the development of biopharmaceuticals, cell therapies, and regenerative medicine products. His leadership roles in the cell therapy industry spanned a multitude of responsibilities including leading early phase development, process optimization, clinical trial execution, and business development. Most recently during his decade-long tenure at Thermo Fisher Scientific, he was responsible for building global strategic alliances and expanding their Cell & Gene Therapy Business Unit.
In his role as Chief Business Development Officer, Eric will lead the expansion of Aspect’s global partnerships with biopharmaceutical innovators, an essential component to advancing breakthrough tissue therapeutic programs that have the potential to profoundly impact patients.
About Aspect Biosystems
Aspect Biosystems is a privately held biotechnology platform company pioneering the microfluidic 3D bioprinting of human tissues. The Company’s proprietary technology has the potential to shape every aspect of human health by enabling the creation of human tissues for medical research, therapeutic discovery, and regenerative medicine. Aspect is focused on partnering with academic institutions and biopharma companies to facilitate high-value discovery and development. The Company is also advancing internal tissue therapeutic programs for regenerative medicine, with an initial focus on metabolic diseases and musculoskeletal injuries and disorders. Learn more at www.aspectbiosystems.com.